Analyst firms · Morgan Stanley · CME

Morgan Stanley CME price target and rating history

CME Group Inc. (CME) · Finance

Morgan Stanley rates CME Group Inc. (CME) Overweight with a $301 price target, as of its latest action on Apr 8, 2025. It has published 5 rating actions on CME since July 2021, including 1 upgrade and 0 downgrades. Across 5 firms with a CME price target in the last 12 months, the median target is $305.

Current rating
Overweight
Price target
$301
Median target, all firms
$305
Actions on CME
5

Morgan Stanley price target on CME

$301$259$21720222023202420252026
Morgan Stanley price target on CME, each point a stated target, July 2021 to April 2025.

Every Morgan Stanley rating on CME

How other firms rate CME

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Wells FargoOverweight$301Oct 2, 2026
Deutsche BankHold$270Aug 19, 2026
Keefe, Bruyette & WoodsOutperform$305Jun 18, 2026
Rothschild & Co RedburnBuy$323Jun 11, 2026
Erste GroupHoldJun 5, 2026
Argus ResearchHoldMar 4, 2026
TD CowenBuy$305Jan 14, 2026

Questions about Morgan Stanley and CME

What is Morgan Stanley's price target for CME?
Morgan Stanley's latest stated price target for CME Group Inc. (CME) is $301, from its action on Apr 8, 2025.
What is Morgan Stanley's rating on CME?
Morgan Stanley rates CME Overweight, a bullish rating, as of Apr 8, 2025.
When did Morgan Stanley last change its view on CME?
On Apr 8, 2025, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $301.
How does Morgan Stanley's CME target compare with other analysts?
Across 5 firms with a CME price target in the last 12 months, the median target is $305.

More CME rating histories

All Morgan Stanley ratingsCME news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.